Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 12, Art. 103 (pp. 1266-1277)    |    2011       

»

Metabolomic approach in the diagnosis of astma and copd

Anokhina T.N.1, Anaev E.Kh.1, Chuchalin A.G.1, Revelsky A.I.2, Rodionov A.A.2, Revelsky I.A.2, Alexeev D.V.3, Kudriavtsev V.B.3

Research Institute of Pulmonology FMBA Russia
Faculty of Chemistry, MV Lomonosov Moscow State University
Mechanics and Mathematics, Lomonosov Moscow State University

Brief summary

The search for new non-invasive techniques and biomarkers for the diagnosis of asthma and COPD is a topical problem of modern respiratory medicine. Objective: To assess the potential of metabolomic approach in exhaled breath condensate (EBC) analysis in the diagnosis of asthma and COPD. Methods: 20 patients with COPD exacerbation (age 66,58,5 years; FEV1-57,322,9%pred), 20 patients with asthma exacerbation (age 50,213,2 years; FEV1-71,420,7%pred) and 30 healthy nonsmoking volunteers (age 25,49,6 years, FEV1 - 98,46,8%pred) were enrolled in cross-sectional study. EBC was collected using ECoScreen. Testing for SvOC with different polarity in EBC was conducted by gas chromatography/mass-spectrometry (GC/MS) method. The collected data were analyzed using an algorithm based on linear methods of pattern recognition theory. Results: There was detected more than100 of various semi-volatile organic compounds (SvOC) in ultra-low concentrations in EBC from patients with asthma, COPD and healthy subjects. 33 SvOC were identified. 9 SvOC (2,3–dihydro-1-H-inden-1-on, ethyl citrate, decanol-1, 2-phenoxyethanol and others) have been deemed the most appropriate for solving recognition problem. Mathematical analysis of the available data enabled distinguishing healthy volunteers from the patients with asthma with reliability of 75%, healthy subjects from COPD patients – 85%, and asthma patients from COPD patients – 83%. Conclusion: Metabolomic approach in EBC analysis help us to diagnose asthma and COPD.


Key words

biomarkers, exhaled breath condensate, semi-volatile organic compounds, metabolomics, diagnosis, asthma, COPD.

Reference list

1. Nicholson J.K., Lindon J.C. Systems biology: metabonomics. Nature 2008; 455: 1054-1056.


2. Serkova N.J., Niemann C.U. Pattern recognition and biomarker validation using quantitative 1H-NMR-based metabolomics. Expert Rev Mol Diagn 2006; 6: 717-731.


3. Bateman E.D., Hurd S.S., Barnes P.J. et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31: 143-178.


4. Rabe K.F., Hurd S., Anzueto A. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.


5. Carraro S., Giordano G., Stocchero M., Baraldi E. Exhaled breath condensate: metabolomics. Eur Respir Mon 2010; 49: 231-236.


6. Anaev E.H., Chychalin A.G. Issledovanie kondensata vidihaemogo vozdyha v pylmonologii (obzor zarybejnoi literatyri). Pylmonologiya. 2002. - №2. - s.57-66.


7. Dettmer K., Aronov P.A., Hammock B.D. Mass spectrometry-based metabolomics. Mass Spectrom Rev 2007; 26: 51-78.


8. Coen M., Holmes E., Lindon J.C. et al. NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem Res Toxicol 2008; 21: 9-27.


9. Pan Z., Raftery D. Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal Bioanal Chem 2007; 387: 525-527.


10. De Laurentiis G., Paris D., Melck D. et al. Metabonomic analysis of exhaled breath condensate in adults by nuclear magnetic resonance spectroscopy. Eur Respir J 2008; 32 (5): 1175-1183.


11. Sofia M., Maniscalco M., de Laurentiis G. et al. Exploring airway diseases by NMR-based metabonomics: a review of application to exhaled breath condensate. J Biomed Biotechnol 2011; Vol. 2011, Article 403260, 7 pages.


12. Rodionov A.A., Revelskii A.I., Revelskii I.A. i dr. Hromatomass- spektrometricheskoe opredelenie sredneletychih organicheskih veshestv v kondensate vidihaemogo vozdyha. Mass-spektrometriya. 2007. – T.4. -№2. - s.143-148.


13. Miller M.R., Hankinson J., Brusasco V. et al. ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005; 26 (2): 319-338.


14. Fynkcionalnaya diagnostika v pylmonologii: Prakticheskoe rykovodstvo. Pod red. Chychalina A.G. - M.: Izdatelskii holding «Atmosfera», 2009. – 192 s.


15. Moser B., Bodrogi F., Eibl G. et al. Mass spectrometric profile of exhaled breath – field study by PTR-MS. Respir Physiol Neurobiol 2005; 145: 295-300.


16. Weston A.D., Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res 2004; 3: 179-196.


17. Crameri R. The potential of proteomics and peptidomics for allergy and asthma research. Allergy 2005; 60: 1227-1237.


18. Sepper R., Prikk K. Proteomics: is it an approach to understand the progression of chronic lung disorders? J Proteome Res 2004; 3: 277-281.


19. Dragonieri S., Schot R., Mertens B.J. et al. An electronic nose in the discrimination of patients with asthma and controls. J Allergy Clin Immunol 2007; 120: 856-862.


20. Fabbri L.M., Romagnoli M., Corbetta L. et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 418-424.


21. Bhattacharya S., Srisuma S., Demeo D.L. et al. Molecular biomarkers for quantitative and discrete COPD phenotypes. Am J Respir Cell Mol Biol 2009; 40: 359-367.


22. Gibson P.G., Simpson J.L. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009; 64: 728–735.


23. Brasier A.R., Victor S., Boetticher G. Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines. J Allergy Clin Immunol 2008; 121: 30- 37.


24. Anderson G.P. Endotyping asthma: 2new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372: 1107-1119.


25. Chung K.F., Adcock I.M. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J 2008; 31: 1334-1356.


26. Buszewski B., Kesy M., Ligor T., Amann A. Human exhaled air analytics: biomarkers of diseases. Biomed Chromatogr 2007; 21: 553-566.


27. Higashimoto Y., Yamagata Y., Taya S. et al. Systemic inflammation in chronic obstructive pulmonary disease and asthma: Similarities and differences. Respirology 2008; 13: 128-133.


28. Dragonieri S., Annema J.T., Schot R. et al. An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD. Lung Cancer 2009; 64: 166-170.


29. Fens N., de Nijs S.B., Roldaan A.C. et al. Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. Am J Respir Crit Care Med 2009; 180(11): 1076-1082.


30. Carraro S, Rezzi S, Reniero F, et al. Metabolomics applied to exhaled breath condensate in childhood asthma. Am J Respir Crit Care Med 2007; 175: 986–990.